Novel Concepts Medical's plant-based formula achieves 99% reduction in cancer cell viability

Novel Concepts Medical is proud to announce breakthrough results from its labs in Israel showing that its plant-based formula resulted in over 99% decrease in cell viability of breast cancer cells and lung cancer cells. Each of the cancer tests was performed three times in one of the premier labs in Israel located in Ness Ziona’s science park. The lab results showed:

  • MCF-7 breast cancer, after 48 hours of incubation: a decrease in cell viability of 99.68%
  • A549 lung cancer, after 48 hours of incubation: a decrease in cell viability of 99.65%

Novel Concepts Medical founder, Rachel Alkalay, PhD, said that the company will consider global collaborations in order to make it approachable for any person in the world.

Earlier this year, the company published a successful case study with a colon cancer patient. The study showed improvement with metastases in the patient’s liver and shrinkage of his tumor size after using our plant-based treatment. No side effects were reported of our treatment.

Novel Concepts Medical and its founder have previously been recognized for their work in the field of plant-based treatment. The company received the "Most Pioneering Life Savings Treatments R&D Company – 2023 Middle East" award from Global Health & Pharma Magazine, and Dr. Alkalay won "One of the top 3 innovative and Creative Women Inventors for 2023" award in the FICPI’s World IP Day competition.


Novel Concepts Medical


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
40% of US cancer cases linked to lifestyle choices